Genprex Inc. Common Stock (GNPX)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach a clinical-stage gene-therapy company as I would a speculation, not a business with a moat. Genprex has no reported revenue in any filed period. It lost $16.2 million in fiscal 2025, $21.1 million in fiscal 2024, and $30.9 million in fiscal 2023. In fiscal Q2 2026, the quarter ended 2026-06-30, it lost $4.4 million, or $9.40 per diluted share. Trailing free cash flow is negative $15.6 million, which against a $9.4 million market cap is a negative 165.4% FCF yield—meaning the enterprise is consuming cash far faster than its market value. FairStock's ratios reinforce the risk: Piotroski F-Score is 1/9, Altman Z-Score is -11.34, return on equity is -203.86%, and return on capital employed is -94.46%. At the $2.51 close on 2026-10-13, FairStock's P/B is 0.09. A low price-to-book might tempt a Graham investor, but book value here is not a stream of earnings; it is cash being spent on trials. The 52-week range of $0.42 to $34.25 shows extreme volatility. There is no demonstrated competitive moat because there is no approved product, no revenue, and only 13 employees. The Lynch category is 'none' precisely because it has lost money in each of the last four years. Growth is not meaningful without revenue. Until I see trial success, a financing plan that does not destroy shareholders, and a path to positive cash flow, I can only view this as a lottery ticket, not an investment.

In plain English: Genprex is a tiny clinical-stage biotech with 13 employees trying to develop gene therapies for cancer and diabetes. It has no reported revenue and has lost money in each of the last four years, including $16.2 million in fiscal 2025. The shares may look cheap compared with the company's reported accounting value, but the company is burning cash and has no approved product, so the business looks weak.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer